Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Increased Nucleosomal DNA Fragmentation in Leukocytes of Thalassemia Patients.

Patrick B Walter, PhD, John B Porter, MD, Patricia Evans, PhD, Janet Kwiatkowski, MD, Ellis J. Neufeld, MD, PhD, Thomas D. Coates, MD, Patricia Giardina, MD, Robert jW Grady, PhD, Elliott Vichinsky, MD, Nancy F. Olivieri, MD, Felicia Trachtenberg, PhD, Daniele Alberti, MD, Ellen Fung, PhD, Bruce Ames, PhD, Annie Lui, BS, Paul Harmatz, MD

Blood (2008) 112 (11): 1868.

https://doi.org/10.1182/blood.V112.11.1868.1868

Published: 2008

Journal Articles

Leukocyte Apoptosis and Mitochondrial Dysfunction in β-Thalassemia Patients Treated with Deferasirox or Deferoxamine.

Patrick B. Walter, PhD, John Porter, MD, Patricia Evans, PhD, Janet L. Kwiatkowski, MD, Ellis J. Neufeld, MD, Thomas Coates, MD, Patricia J. Giardina, MD, Robert W. Grady, PhD, Elliott Vichinsky, MD, Nancy F. Olivieri, MD, Felicia Trachtenberg, PhD, Daniele Alberti, MD, Jaymes Holland, PhD, Ellen Fung, PhD, Bruce Ames, PhD, Annie Lui, BS, Paul Harmatz, MD

Blood (2007) 110 (11): 2773.

https://doi.org/10.1182/blood.V110.11.2773.2773

Published: 2007

Journal Articles

A Phase II Study with ICL670 (Exjade®), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload.

John Porter, MD, Elliot Vichinsky, MD, Christian Rose, MD, Antonio Piga, MD, Nancy Olivieri, MD, Norbert Gattermann, MD, Johan Maertens, MD, Bertrand Rabault, PhD, Insa Gathmann, MSc, Daniele Alberti, MD

Blood (2004) 104 (11): 3193.

https://doi.org/10.1182/blood.V104.11.3193.3193

Published: 2004

Journal Articles

Once-Daily Treatment with the Oral Iron Chelator ICL670 (Exjade®): Results of a Phase II Study in Pediatric Patients with β-Thalassemia Major.

Antonio Piga, MD, Renzo Galanello, MD, Maria Loreta Foschini, MD, Antonella Zappu, MD, Elena Bordone, MD, Filomena Longo, MD, Gian-Luca Forni, MD, Antonella Lavagetto, MD, Yves Bertrand, MD, Henry Maseruka, PhD, Nicola Latham, MSc, Daniele Alberti, MD

Blood (2004) 104 (11): 3614.

https://doi.org/10.1182/blood.V104.11.3614.3614

Published: 2004

Journal Articles

Phase III Evaluation of Once-Daily, Oral Therapy with ICL670 (Exjade®) Versus Deferoxamine in Patients with β-Thalassemia and Transfusional Hemosiderosis.

Maria Cappellini, MD, Mohamed Bejaoui, MD, Silverio Perrotta, MD, Leyla Agaoglu, MD, Antonios Kattamis, MD, Patricia Giardina, MD, Gritta Janka-Schaub, MD, Herbert Opitz, PhD, Catherine Ressayre-Djaffer, PhD, Daniele Alberti, MD

Blood (2004) 104 (11): 3619.

https://doi.org/10.1182/blood.V104.11.3619.3619

Published: 2004

NARROW

Increased Nucleosomal DNA Fragmentation in Leukocytes of Thalassemia Patients.

Leukocyte Apoptosis and Mitochondrial Dysfunction in β-Thalassemia Patients Treated with Deferasirox or Deferoxamine.

A Phase II Study with ICL670 (Exjade®), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload.

Once-Daily Treatment with the Oral Iron Chelator ICL670 (Exjade®): Results of a Phase II Study in Pediatric Patients with β-Thalassemia Major.

Phase III Evaluation of Once-Daily, Oral Therapy with ICL670 (Exjade®) Versus Deferoxamine in Patients with β-Thalassemia and Transfusional Hemosiderosis.

Email alerts

ASH Publications

American Society of Hematology

Increased Nucleosomal DNA Fragmentation in Leukocytes of Thalassemia Patients.

Leukocyte Apoptosis and Mitochondrial Dysfunction in β-Thalassemia Patients Treated with Deferasirox or Deferoxamine.

A Phase II Study with ICL670 (Exjade®), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload.

Once-Daily Treatment with the Oral Iron Chelator ICL670 (Exjade®): Results of a Phase II Study in Pediatric Patients with β-Thalassemia Major.

Phase III Evaluation of Once-Daily, Oral Therapy with ICL670 (Exjade®) Versus Deferoxamine in Patients with β-Thalassemia and Transfusional Hemosiderosis.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only